2026-08-29T12:39:50Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/272672026-02-25T01:21:32Zcom_20.500.12105_19604com_20.500.12105_2051col_20.500.12105_19605

00925njm 22002777a 4500 dc Garcia-Pavia, P author Rapezzi, C author Adler, Y author Arad, M author Basso, C author Brucato, A author Burazor, I author Caforio, ALP author Damy, T author Eriksson, U author Fontana, M author Gillmore, JD author Gonzalez-Lopez, E author Grogan, M author Heymans, S author Imazio, M author Kindermann, I author Kristen, A author Maurer, MS author Merlini, G author Pantazis, A author Pankuweit, S author Rigopoulos, AG author Linhart, A author 2021-04-21 Cardiac amyloidosis is a serious and progressive infiltrative disease that is caused by the deposition of amyloid fibrils at the cardiac level. It can be due to rare genetic variants in the hereditary forms or as a consequence of acquired conditions. Thanks to advances in imaging techniques and the possibility of achieving a non-invasive diagnosis, we now know that cardiac amyloidosis is a more frequent disease than traditionally considered. In this position paper the Working Group on Myocardial and Pericardial Disease proposes an invasive and non-invasive definition of cardiac amyloidosis, addresses clinical scenarios and situations to suspect the condition and proposes a diagnostic algorithm to aid diagnosis. Furthermore, we also review how to monitor and treat cardiac amyloidosis, in an attempt to bridge the gap between the latest advances in the field and clinical practice. Eur Heart J . 2021 Apr 21;42(16):1554-1568. EUROPEAN HEART JOURNAL https://hdl.handle.net/20.500.12105/27267 Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases